Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats

Journal of Hypertension
J R Paull, R E Widdop

Abstract

It is generally accepted that short-term (4 weeks) inhibition of the renin-angiotensin system (RAS) of young spontaneously hypertensive rats (SHR) in their prehypertensive phase confers long-lasting protection from fully hypertensive levels in adulthood. However, there is very little data pertaining to the effects of such treatment in adult SHR with established hypertension. Therefore, we determined the relative effects of angiotensin converting enzyme (ACE) inhibition (perindopril), AT1 receptor blockade (candesartan cilexetil) and RAS-independent vasodilatation (hydralazine) and their withdrawal in adult SHR, on blood pressure measured by radiotelemetry, as well as on cardiac and vascular structure. Adult male SHR were instrumented with radiotelemetry probes to measure blood pressure and heart rate continuously. SHR were given either vehicle, perindopril (1 mg/kg per day), candesartan cilexetil (2 mg/ kg per day) or hydralazine (30 mg/kg per day) at equieffective depressor doses for 4 weeks (treatment study). Separate groups of animals were also given identical treatments but were then monitored for a further 8 weeks after drug withdrawal (withdrawal study). An indirect in-vivo assessment of whole body vascular hypertrophy (m...Continue Reading

References

Jan 1, 1992·Clinical and Experimental Pharmacology & Physiology. Supplement·M E CooperT Lim-Joon
Sep 1, 1986·Clinical and Experimental Pharmacology & Physiology·M E CooperA E Doyle
Dec 1, 1993·Journal of Cardiovascular Pharmacology·M K BazilR L Webb
Jan 14, 1997·European Journal of Pharmacology·M OjimaK Nishikawa
Mar 1, 1997·Journal of Vascular Research·M E SafarH A Struijker-Boudier
Jul 1, 1997·Journal of Cardiovascular Pharmacology·J S LiE L Schiffrin

❮ Previous
Next ❯

Citations

Jan 30, 2004·Regulatory Peptides·Sim Meng KwoonXu Xiao Guang
Mar 1, 2003·Regulatory Peptides·M K Sim, X S Qui
Dec 14, 2011·Canadian Journal of Physiology and Pharmacology·Inés López-IslasJosé A Terrón
Jul 22, 2009·European Journal of Pharmacology·Jacinthe LemayDenis deBlois
Dec 24, 2005·Autonomic & Autacoid Pharmacology·D Godínez-HernándezR Villalobos-Molina
Apr 25, 2015·Advances in Chronic Kidney Disease·John M Hamlyn, Paolo Manunta
Jan 11, 2017·Clinical and Experimental Hypertension : CHE·Jessica Edith RodríguezSantiago Villafaña
Apr 10, 2010·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·W A RochaJ G Mill
Sep 10, 2011·Journal of Hypertension·Kate M Denton
Nov 26, 2010·Journal of Cardiovascular Pharmacology·Gaëlle NaeltenMing Lo
Nov 25, 2005·Journal of Cardiovascular Pharmacology·Bart WestendorpHendrik Buikema
May 31, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Lei LüYi-Chun Zhu
Apr 29, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Sadman BhuiyanChrishan S Samuel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.